Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37809 NeuroBo Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 47-2389984 (State or ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2020 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37809 NeuroBo Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 47-2389984 ( ...

PART I FINANCIAL INFORMATION [Financial Statements (unaudited)](index=3&type=section&id=ITEM%201%3A%20Financial%20Statements%20%28unaudited%29) This section presents the unaudited condensed consolidated financial statements, including balance sheets, statements of operations, changes in equity, and cash flows, with notes detailing key events and financial health [Condensed Consolidated Balance Sheets](index=3&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of June 30, 2020, total assets were **$15,552 thousand**, primarily cash, with total liabilities of **$3,214 thousand** and stockholders' equity of **$12,338 thousand** Condensed Consolidated Balance Sheets (in thousands) | | June 30, 2020 (unaudited) | December 31, 2019 | | :--- | :--- | :--- | | **Total current assets** | $15,243 | $14,118 | | **Total assets** | $15,552 | $14,468 | | **Total current liabilities** | $3,132 | $2,082 | | **Total liabilities** | $3,214 | $2,176 | | **Total stockholders' equity** | $12,338 | $12,292 | | **Total liabilities and stockholders' equity** | $15,552 | $14,468 | [Condensed Consolidated Statements of Operations and Comprehensive Loss](index=4&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) For the three and six months ended June 30, 2020, net losses were **$2,384 thousand** and **$7,114 thousand**, respectively, primarily due to increased general and administrative expenses Condensed Consolidated Statements of Operations (in thousands) | | Three Months Ended June 30, | Six Months Ended June 30, | | :--- | :--- | :--- | | | **2020** | **2019** | **2020** | **2019** | | Research and development | $674 | $948 | $2,826 | $2,748 | | General and administrative | $1,718 | $939 | $4,315 | $1,590 | | **Total operating expenses** | **$2,392** | **$1,887** | **$7,141** | **$4,338** | | **Loss from operations** | **($2,392)** | **($1,887)** | **($7,141)** | **($4,338)** | | **Net loss** | **($2,384)** | **($1,901)** | **($7,114)** | **($4,365)** | | **Net loss per share, basic and diluted** | **($0.15)** | **($0.37)** | **($0.44)** | **($0.84)** | [Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit)](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Changes%20in%20Stockholders%27%20Equity%20%28Deficit%29) Stockholders' equity increased from **$12,292 thousand** to **$12,338 thousand** by June 30, 2020, driven by a **$7,500 thousand** equity financing largely offset by a **$7,114 thousand** net loss - In the second quarter of 2020, the company issued **750,000 shares** of common stock in an equity financing, generating **$7,500 thousand** in gross proceeds[12](index=12&type=chunk) - The net loss for the six months ended June 30, 2020 was **$7,114 thousand** (reported as **$4,730 thousand** in Q1 and **$2,384 thousand** in Q2), which reduced stockholders' equity[12](index=12&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) For the six months ended June 30, 2020, net cash used in operating activities was **$6,462 thousand**, offset by **$6,858 thousand** from financing, resulting in a **$394 thousand** net increase in cash Cash Flow Summary for the Six Months Ended June 30 (in thousands) | | 2020 | 2019 | | :--- | :--- | :--- | | Net cash used in operating activities | $(6,462) | $(2,416) | | Net cash used in investing activities | $(2) | $(25) | | Net cash provided by financing activities | $6,858 | $24,175 | | **Net increase in cash and restricted cash** | **$394** | **$21,734** | | Cash and restricted cash at end of period | $14,298 | $24,588 | [Notes to Condensed Consolidated Financial Statements](index=8&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Notes detail significant events, including halting NB-01 Phase 3 trials due to COVID-19, postponing NB-02 trials, a going concern warning with cash of **$14,300 thousand** sufficient only into Q2 2021, and a **$7,500 thousand** equity financing - Due to the COVID-19 pandemic, the company halted all work on Phase 3 clinical trials for its lead candidate, **NB-01**, in the first quarter of 2020 and terminated its CRO contracts[24](index=24&type=chunk) - The company is preparing an IND application for **NB-02** but intends to postpone the first human clinical trials until the first half of 2021, contingent on improved global conditions[26](index=26&type=chunk) - The company has experienced net losses since inception, with an accumulated deficit of **$44,000 thousand** as of June 30, 2020, raising substantial doubt about its ability to continue as a going concern, with cash expected to last only into Q2 2021[40](index=40&type=chunk)[42](index=42&type=chunk)[43](index=43&type=chunk) - On April 13, 2020, the company sold **750,000 shares** of common stock at **$10 per share** in a registered direct offering, resulting in gross proceeds of **$7,500 thousand**[105](index=105&type=chunk)[106](index=106&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)](index=34&type=section&id=ITEM%202%3A%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses financial condition and operations, highlighting the halt of **NB-01** Phase 3 trials due to COVID-19, increased net loss from higher G&A expenses, and substantial doubt about going concern with **$14,300 thousand** cash projected only into Q2 2021 - Due to the COVID-19 pandemic and to conserve financial resources, the company has indefinitely postponed Phase 3 clinical trials for **NB-01** and is exploring alternative regulatory pathways, such as for an orphan drug[140](index=140&type=chunk)[141](index=141&type=chunk)[142](index=142&type=chunk) - The company's cash of **$14,300 thousand** as of June 30, 2020, is expected to fund operations into the second quarter of 2021, which raises substantial doubt about its ability to continue as a going concern[146](index=146&type=chunk)[151](index=151&type=chunk) Comparison of Operating Results (in thousands) | | Three Months Ended June 30, | Six Months Ended June 30, | | :--- | :--- | :--- | | | **2020** | **2019** | **2020** | **2019** | | Research and development | $674 | $948 | $2,826 | $2,748 | | General and administrative | $1,718 | $939 | $4,315 | $1,590 | | **Net loss** | **($2,384)** | **($1,901)** | **($7,114)** | **($4,365)** | - G&A expenses for the six months ended June 30, 2020, increased by **$2,700 thousand** compared to the prior year, mainly due to costs of operating as a public company, including legal, audit, and D&O insurance premiums[177](index=177&type=chunk) [Quantitative and Qualitative Disclosures about Market Risk](index=46&type=section&id=ITEM%203%3A%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) The company states this item is not applicable, indicating no significant exposure to market risks requiring quantitative and qualitative disclosure - This section is **not applicable** to the company for the reporting period[206](index=206&type=chunk) [Controls and Procedures](index=46&type=section&id=ITEM%204%3A%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were not effective as of June 30, 2020, due to a material weakness in accounting for clinical trial costs, with remediation efforts underway - Management concluded that disclosure controls and procedures were **not effective** as of June 30, 2020, due to a material weakness[210](index=210&type=chunk) - The material weakness relates to internal control deficiencies in accounting for clinical trial costs and related supply materials, which led to misstatements discovered during the audit/review process[211](index=211&type=chunk) - Remediation efforts are underway, including adding more experienced accounting personnel, improving clinical site expense monitoring, and retaining qualified outside consultants[214](index=214&type=chunk) PART II OTHER INFORMATION [Legal Proceedings](index=49&type=section&id=ITEM%201%3A%20Legal%20Proceedings) The company is not currently involved in any legal proceedings expected to have a material adverse effect on its business - The company is **not currently a party** to any legal proceedings expected to have a material adverse effect on its business[216](index=216&type=chunk) [Risk Factors](index=49&type=section&id=ITEM%201A%3A%20Risk%20Factors) This section updates risk factors, focusing on postponing **NB-01** Phase 3 trials due to COVID-19, risks of alternative development pathways, and broader pandemic impacts on supply chains, clinical trials, and capital access - The company has postponed the initiation of Phase 3 clinical trials for **NB-01** and terminated all related CRO agreements due to the business environment and the COVID-19 pandemic[218](index=218&type=chunk)[219](index=219&type=chunk) - The company is considering alternative pathways for **NB-01**, such as development as an orphan drug, but there is no assurance of success and this path carries its own risks, such as difficulty in conducting clinical trials for rare diseases[220](index=220&type=chunk)[221](index=221&type=chunk) - The COVID-19 pandemic poses ongoing risks to the business, including potential disruption of the supply chain, manufacturing, clinical trial enrollment, and the ability to secure future financing[224](index=224&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=51&type=section&id=ITEM%202%3A%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company indicates that this item is **not applicable** for the reporting period - This section is **not applicable**[225](index=225&type=chunk) [Default upon Senior Securities](index=51&type=section&id=ITEM%203%3A%20Default%20upon%20Senior%20Securities) The company indicates that this item is **not applicable**, signifying no defaults on senior securities have occurred - This section is **not applicable**[226](index=226&type=chunk) [Mine Safety Disclosures](index=51&type=section&id=ITEM%204%3A%20Mine%20Safety%20Disclosures) The company indicates that this item is **not applicable**, as it is not involved in mining operations - This section is **not applicable**[227](index=227&type=chunk) [Other Information](index=51&type=section&id=ITEM%205%3A%20Other%20Information) The company disclosed a five-year manufacturing and supply agreement with Dong-A ST on June 7, 2020, for **NB-02** drug product and placebo for R&D and its first human clinical trial - On June 7, 2020, the company entered into a manufacturing and supply agreement with **Dong-A ST** for its **NB-02** drug product and placebo to be used in R&D and the first human clinical trial[228](index=228&type=chunk) [Exhibits](index=52&type=section&id=ITEM%206%3A%20Exhibits) This section lists exhibits filed with the 10-Q report, including documents related to the April 2020 equity financing, the new manufacturing agreement for **NB-02**, and officer certifications - Key exhibits filed with this report include documents related to the April 2020 equity financing and the new manufacturing agreement for **NB-02** with **Dong-A ST** dated June 7, 2020[231](index=231&type=chunk) SIGNATURES - The quarterly report was signed on **August 11, 2020**, by **Richard Kang**, President and Chief Executive Officer[235](index=235&type=chunk)

Financial Performance - The company reported a net loss of $4,730,000 for the three months ended March 31, 2020, compared to a net loss of $2,464,000 for the same period in 2019, indicating an increase in loss of approximately 91.8%[10]. - Total operating expenses for Q1 2020 were $4,749,000, up from $2,451,000 in Q1 2019, reflecting an increase of approximately 93.6%[10]. - The company reported a comprehensive loss of $4,764,000 for the three months ended March 31, 2020, compared to a comprehensive loss of $2,466,000 for the same period in 2019[10]. - The company expects to continue incurring net losses and negative cash flows from operations into the foreseeable future, raising substantial doubt about its ability to continue as a going concern[40]. - The company has experienced net losses and negative cash flows from operating activities since inception, relying on debt and equity financings to fund operations[40]. Assets and Liabilities - As of March 31, 2020, total assets decreased to $11,535,000 from $14,468,000 as of December 31, 2019, representing a decline of approximately 20.2%[8]. - Total current assets decreased from $14,118,000 as of December 31, 2019, to $11,211,000 as of March 31, 2020, a decline of approximately 20.5%[8]. - Total liabilities increased from $2,176,000 as of December 31, 2019, to $3,795,000 as of March 31, 2020, an increase of approximately 74.4%[8]. - Cash and restricted cash at the end of Q1 2020 totaled $9,814,000, down from $13,923,000 at the beginning of the period, marking a decrease of approximately 29.5%[15]. - The company had $9.8 million in cash as of March 31, 2020, which is expected to fund operations through the first quarter of 2021[37][41]. Research and Development - Research and development expenses for Q1 2020 were $2,152,000, compared to $1,800,000 in Q1 2019, an increase of approximately 19.6%[10]. - The company is considering marketing NB-01 as a nutraceutical product and may conduct feasibility studies for a rare disease relevant to NB-01[25]. - The company plans to postpone the first human clinical trials for NB-02 until global health conditions improve, aiming to commence in Q1 2021[26]. - The company has directed its CRO partners to cease all work on Phase 3 clinical trials for NB-01 due to difficulties in the short to medium term[24]. - The company is supporting activities to lift the FDA's partial clinical hold on Gemcabene and is exploring trial opportunities in China[27]. Stock and Financing - The company raised a total of $16.8 million from the issuance of Series A redeemable convertible preferred stock and $24.2 million from Series B redeemable convertible preferred stock in 2019[38]. - The company raised $7.5 million in gross proceeds from a registered direct offering of 750,000 shares at $10 per share on April 16, 2020[129]. - The company has a weighted average of 15,670,800 common shares outstanding for Q1 2020, compared to 5,166,812 shares in Q1 2019, indicating a substantial increase in shares outstanding[10]. - The company’s stockholders may experience significant dilution if additional funds are raised through equity securities[41]. - The company has not recognized any revenue under the Beijing SL Agreement as of March 31, 2020[90]. Agreements and Commitments - The company agreed to make milestone payments totaling up to $37 million under the Pfizer Agreement, contingent on achieving specific milestones[79]. - The Beijing SL Agreement includes a non-refundable upfront payment of $2.5 million, received in October 2019, with additional milestone payments totaling up to $26 million possible[92]. - Future minimum payments under the cultivation service agreement with Xiehecheng are projected to total $572,000 from 2020 to 2022[77]. - The company has committed up to $1 million to support the further development of Gemcabene under the Contingent Value Rights Agreement[70]. - The exclusive license agreement with Pfizer for Gemcabene includes milestone and royalty payments on future sales[78]. Expenses and Liabilities - Accrued liabilities increased to $2,411,000 as of March 31, 2020, up from $1,422,000 in the previous year, primarily due to external research and development expenses[66]. - The Company incurred approximately $675,000 in termination expenses related to contract research organizations (CROs) during the first quarter of 2020[66]. - The New Boston Lease has a monthly rental cost of $21, with total minimum lease payments projected at $214,000 through December 31, 2020[73]. - The total lease liabilities recognized on the consolidated balance sheet as of March 31, 2020, amounted to $111,000, with a long-term portion of $89,000[76]. - The New Boston Lease and Boston Lease expenses totaled $115,000 for the three months ended March 31, 2020, including a termination fee of $83,000[73].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37809 NeuroBo Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) h Delaware 47‑2389984 (State o ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) Commission file number 001-37809 Gemphire Therapeutics Inc. (Exact name of Registrant as specified in its charter) Delaware 47‑2389984 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) P.O. Box 130235, Ann Arbor, MI 48113 (Address of principal executive offices) (Zip Code) (734) 245‑1700 Non-accelerated filer ☐ Smaller reporting company ☒ Emerging growth ...

Table of Contents Commission file number 001-37809 Gemphire Therapeutics Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 (Exact name of Registrant as specified in its charter) Form 10-Q (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) (Mark One) Delaware 47‑2389984 17199 N. Laurel Park Drive, Suite 401, Livonia, MI 48152 (Address of principal executive offices) (Zip Code) (734) 245‑1700 (Registrant's telephone number, including area ...

PART I - FINANCIAL INFORMATION [Financial Statements](index=3&type=section&id=ITEM%201%3A%20Financial%20Statements) Gemphire Therapeutics reported a net loss of **$3.8 million** for Q1 2019, an improvement from **$7.2 million** in Q1 2018, driven by reduced R&D expenses, but with **$5.5 million** cash and declining assets, raising substantial doubt about its going concern Condensed Balance Sheet Highlights (in thousands) | | March 31, 2019 | December 31, 2018 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $ 5,510 | $ 18,954 | | Total current assets | $ 6,106 | $ 19,686 | | Total assets | $ 6,158 | $ 19,694 | | **Liabilities and Stockholders' Equity** | | | | Total current liabilities | $ 1,712 | $ 11,919 | | Total liabilities | $ 1,712 | $ 11,920 | | Total stockholders' equity | $ 4,446 | $ 7,774 | Condensed Statements of Comprehensive Loss (in thousands, except per share amounts) | | For the Three Months Ended March 31, | | | :--- | :--- | :--- | | | **2019** | **2018** | | General and administrative | $ 1,407 | $ 2,087 | | Research and development | $ 1,393 | $ 4,977 | | Total operating expenses | $ 2,800 | $ 7,064 | | Net loss | $ (3,801) | $ (7,224) | | Net loss per share (basic and diluted) | $ (0.27) | $ (0.58) | Condensed Statements of Cash Flows Highlights (in thousands) | | For the Three Months Ended March 31, | | | :--- | :--- | :--- | | | **2019** | **2018** | | Net cash used in operating activities | $ (3,170) | $ (7,236) | | Net cash (used in) provided by financing activities | $ (10,259) | $ 23,224 | | Net (decrease) increase in cash | $ (13,429) | $ 15,988 | | Cash, cash equivalents and restricted cash at end of period | $ 5,525 | $ 34,461 | - The company has incurred losses since inception, with an accumulated deficit of **$87.9 million** as of March 31, 2019, and its cash balance of **$5.5 million** is insufficient to fund operations for the next twelve months, raising substantial doubt about its ability to continue as a going concern[27](index=27&type=chunk)[28](index=28&type=chunk) - On January 28, 2019, the company fully prepaid its term loan with Silicon Valley Bank, including approximately **$8.9 million** in principal and interest and a **$1.0 million** final payment fee, leading to **$0.8 million** in unamortized note discounts recognized as interest expense[50](index=50&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=20&type=section&id=ITEM%202%3A%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) The company's Q1 2019 net loss decreased to **$3.8 million** from **$7.2 million** in Q1 2018, driven by a **$3.6 million** reduction in R&D expenses due to a partial clinical hold on gemcabene, with **$5.5 million** cash projected to last only into Q3 2019, necessitating additional capital and strategic alternatives Comparison of Operating Results (in thousands) | | For the Three Months Ended March 31, | Change | | :--- | :--- | :--- | :--- | | | **2019** | **2018** | | | General and administrative | $ 1,407 | $ 2,087 | $ (680) | | Research and development | $ 1,393 | $ 4,977 | $ (3,584) | | Total operating expenses | $ 2,800 | $ 7,064 | $ (4,264) | | Net loss | $ (3,801) | $ (7,224) | $ 3,423 | - R&D expenses decreased by **$3.6 million** in Q1 2019 compared to Q1 2018, primarily due to reduced clinical trial activities while the company works to resolve the FDA's partial clinical hold on gemcabene[132](index=132&type=chunk) - As of March 31, 2019, the company had **$5.5 million** in cash and cash equivalents, which management believes are sufficient to fund operations only into the third quarter of 2019, necessitating additional capital for continued development[137](index=137&type=chunk)[149](index=149&type=chunk) - The FDA has maintained a partial clinical hold on gemcabene, preventing studies longer than six months, with the company conducting additional preclinical studies for submission in Q4 2019, and an End of Phase 2 meeting contingent on the hold being lifted[110](index=110&type=chunk) - In December 2018, the Board of Directors initiated a review of strategic alternatives to maximize stockholder value, engaging Ladenburg Thalmann & Co. Inc. as a strategic financial advisor[113](index=113&type=chunk) [Quantitative and Qualitative Disclosures about Market Risk](index=31&type=section&id=ITEM%203%3A%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) The company indicates that this section is not applicable - The company has indicated that this section is not applicable[170](index=170&type=chunk) [Controls and Procedures](index=31&type=section&id=ITEM%204%3A%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and procedures were effective as of March 31, 2019, with no material changes to internal control over financial reporting during the quarter - Based on an evaluation as of March 31, 2019, the company's principal executive and financial officer concluded that its disclosure controls and procedures were effective[173](index=173&type=chunk) - There were no changes in the company's internal control over financial reporting during the quarter ended March 31, 2019, that have materially affected, or are reasonably likely to materially affect, its internal control[174](index=174&type=chunk) PART II - OTHER INFORMATION [Legal Proceedings](index=31&type=section&id=ITEM%201%3A%20Legal%20Proceedings) The company may face ordinary course claims and lawsuits, but believes their resolution will not materially adversely affect its financial position or results - The Company may be subject to claims and lawsuits arising primarily in the ordinary course of business, but believes their ultimate resolution will not have a material adverse effect on its financial position, results of operations, or cash flows[175](index=175&type=chunk) [Risk Factors](index=32&type=section&id=ITEM%201A%3A%20Risk%20Factors) The company faces delisting risk due to non-compliance with Nasdaq's **$10 million** equity requirement, prompting a plan to transfer to the Nasdaq Capital Market with a **$2.5 million** equity requirement, as failure to comply could negatively impact stock liquidity and capital raising - On March 20, 2019, the company received a Nasdaq notice for non-compliance with the **$10 million** minimum stockholders' equity requirement for continued listing on the Nasdaq Global Market[180](index=180&type=chunk) - On May 6, 2019, the company submitted a plan to regain compliance by applying to transfer its common stock listing to The Nasdaq Capital Market, which has a lower minimum stockholders' equity requirement of **$2.5 million**[181](index=181&type=chunk) - If delisted, the company's common stock could be subject to penny stock regulations, adversely affecting its market liquidity, price, and ability to obtain financing[183](index=183&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=32&type=section&id=ITEM%202%3A%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company indicates that this section is not applicable - The company has indicated that this section is not applicable[186](index=186&type=chunk) [Default upon Senior Securities](index=33&type=section&id=ITEM%203%3A%20Default%20upon%20Senior%20Securities) The company indicates that this section is not applicable - The company has indicated that this section is not applicable[187](index=187&type=chunk) [Mine Safety Disclosures](index=33&type=section&id=ITEM%204%3A%20Mine%20Safety%20Disclosures) The company indicates that this section is not applicable - The company has indicated that this section is not applicable[188](index=188&type=chunk) [Other Information](index=33&type=section&id=ITEM%205%3A%20Other%20Information) This section reiterates the company's Nasdaq non-compliance notice received on March 20, 2019, for failing to meet the **$10 million** minimum stockholders' equity, and its plan submitted on May 6, 2019, to transfer to the Nasdaq Capital Market for compliance - This section repeats information from the Risk Factors section regarding the Nasdaq non-compliance notice received on March 20, 2019, and the subsequent plan submitted on May 6, 2019, to transfer to the Nasdaq Capital Market[189](index=189&type=chunk)[190](index=190&type=chunk) [Exhibits](index=34&type=section&id=ITEM%206%3A%20Exhibits) This section lists exhibits filed with the 10-Q report, including corporate governance documents, officer certifications (SOX 302 & 906), and XBRL data files - Lists filed exhibits, including corporate governance documents, officer certifications (SOX 302 & 906), and XBRL data files[192](index=192&type=chunk) Signatures The report was duly signed on May 9, 2019, by Steven Gullans, President and Chief Executive Officer, who also serves as Principal Executive Officer and Principal Financial Officer - The report was signed on May 9, 2019, by Steven Gullans, President and Chief Executive Officer (Principal Executive Officer and Principal Financial Officer)[196](index=196&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) Table of Contents ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37809 Gemphire Therapeutics Inc. (Exact name of Registrant as specified in its charter) Delaware 47‑2389984 (State or oth ...